RCT of a Written Action Plan vs. Usual Care in Children With Acute Asthma

This study has been completed.
Sponsor:
Collaborator:
Fonds de la Recherche en Santé du Québec
Information provided by (Responsible Party):
Francine Ducharme, McGill University Health Center
ClinicalTrials.gov Identifier:
NCT00381355
First received: September 25, 2006
Last updated: March 25, 2014
Last verified: March 2014
  Purpose

The objective of the proposed large, high-intensity, randomised controlled trial is to evaluate the real-life effectiveness of providing a written action plan to asthmatic children discharged from the emergency department (ED) or hospital on the short-term adherence to written recommendations (including medication, attendance to asthma education and medical follow-up). main outcome is adherence to prescribed inhaled preventive medication measured by an electronic counter. Secondary outcomes include attendance to asthma education and to medical follow-up, serving by pharmacy of prescription of oral steroids, as well as asthma control measured by questionnaire (Asthma Quiz for Kidz),2 use of rescue ß2-agonists, relapse to emergency room.


Condition Intervention Phase
Asthma
Procedure: Written Action Plan for Acute Asthma
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind
Official Title: Does the Use of a New Written Action Plan Increase Short-term Adherence to Prescribed Medication and Asthma Control in Children Treated for an Asthma Attack in the Emergency Department: A Randomized Controlled Trial.

Resource links provided by NLM:


Further study details as provided by McGill University Health Center:

Primary Outcome Measures:
  • Adherence rate to daily inhaled steroids, reported as the ratio of the sum of number of recorded over prescribed activation per day during the 28 days following the index visit.

Secondary Outcome Measures:
  • Proportion of children filling their prescription of oral steroids
  • Use of rescue B2-agonists measured by dose counter
  • Quality of life in children aged 7 years and older, measured by the Juniper Questionnaire
  • Quality of life of their parent, measured by the Juniper Questionnaire
  • Asthma control, measured by the Asthma Quiz for Kidz
  • Attendance to asthma education
  • Attendance to regular medical review
  • Return visit rate to the ED

Enrollment: 218
Study Start Date: October 2006
Primary Completion Date: April 2007 (Final data collection date for primary outcome measure)
Detailed Description:

The objective of the proposed large, high-intensity, randomised controlled trial is to evaluate the real-life effectiveness of providing a written action plan to asthmatic children discharged from the emergency department (ED) or hospital on the short-term adherence to written recommendations (including medication, attendance to asthma education and medical follow-up). Contrary to the traditional definition of a written action plan,1 i.e., a set of written instructions to follow in case of an exacerbation, we propose to test a new written action plan based on the innovative concept that emphasises the key elements associated with good asthma care: (1) use of preventive medication, (2) need for asthma education, (3) need for regular medical review, (4) environmental control and (5) instructions for use of rescue medication. The main outcome is adherence to prescribed inhaled preventive medication measured by an electronic counter. Secondary outcomes include attendance to asthma education and to medical follow-up, serving by pharmacy of prescription of oral steroids, as well as asthma control measured by questionnaire (Asthma Quiz for Kidz),2 use of rescue ß2-agonists, relapse to emergency room. Because of the recommended medical follow-up where primary care physicians may recommend a change in the preventive treatment initiated in hospital, only short-term outcomes occurring within 28 days of the index visit will be considered as associated with the use of the written action plan. We have purposely designed this trial to test the additional benefit of the intervention over the usual care, recognizing the heterogeneity in the amount of asthma information provided within the time constraints of the emergency room by our 90 physicians. To provide clinically meaningful and generalisable information, the eligibility criteria for study entry have been limited to the bare necessity to confirm the diagnosis of asthma. The randomisation will be stratified on age to reflect the target interlocutor of the written action plan, namely the parents for the 60% children aged < 6 years, the child and parent pair for the 40% children aged 7 to 12 years old, and the adolescents for the 10% patients aged 13-17 years old. We anticipate important variations in the characteristics of enrolled patients reflecting the real heterogeneity of the emergency department attendees, namely in the severity of baseline exacerbation (55% mild, 35% moderate, 10% severe), ownership of a written action plan (15%), prior asthma education (30%), use of daily preventive medicine (25%), etc, all of which may influence the adherence rate to the written action plan. To compensate this heterogeneity in patients' characteristics and provided instructions, the power of the trial to identify a clinically important difference in the main outcome has been set at 90% rather than the traditional 80%. The strength of the proposed study is clearly the assessment the real-life effectiveness of providing a new concept written action plan to a high-risk population to improve the main obstacles to good asthma control, namely adherence to preventive medication and attendance to asthma education and regular review.

  Eligibility

Ages Eligible for Study:   1 Year to 17 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Children will be eligible, whether they are discharged from the ED or following a hospital admission, if:

  1. aged 1 to 17 years;
  2. presenting with acute asthma as per the 2003 Canadian Consensus Statement - The ED physician will be responsible for confirming the diagnosis of asthma;
  3. requiring at least one nebulisation of salbutamol;
  4. the ED physician plans on prescribing the patient inhaled steroids and/or inhaled b2-agonists delivered by metered dose inhaler or continuing a previously prescribed inhaled steroid;
  5. the patient intends to stay in the Province of Quebec in the next 45 days;
  6. the patient (and their parents) have a good understanding of written and spoken French or English.

Exclusion Criteria:

Children will be excluded if they:

  1. currently take asthma medications (ß2-agonist and/or inhaled steroids) using a turbuhaler or diskus, because these delivery devices cannot be fitted with Doser CT, a computerized electronic dose counter for metered dose inhalers;
  2. have another chronic lung disease (other than asthma) such as cystic fibrosis or bronchopulmonary dysplasia;
  3. have known hypersensitivity to inhaled salbutamol or fluticasone.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00381355

Locations
Canada, Quebec
Ste-Justine Hospital
Montréal, Quebec, Canada, H3T 1C5
Sponsors and Collaborators
McGill University Health Center
Fonds de la Recherche en Santé du Québec
Investigators
Principal Investigator: Francine M. Ducharme, MD, MSc CHUS-Ste Justine Hospital
  More Information

No publications provided by McGill University Health Center

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Francine Ducharme, Principal Investigator, McGill University Health Center
ClinicalTrials.gov Identifier: NCT00381355     History of Changes
Other Study ID Numbers: 051703
Study First Received: September 25, 2006
Last Updated: March 25, 2014
Health Authority: Canada: Health Canada

Keywords provided by McGill University Health Center:
asthma
children
written action plan
education
guided self-management
efficacy
compliance
b2-agonists
inhaled corticosteroids
oral steroids
relapse
randomised controlled trial
emergency department

Additional relevant MeSH terms:
Asthma
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases

ClinicalTrials.gov processed this record on September 15, 2014